BIVI dividend history

-Topline Data Release Targeted Late Summer 2026- CARSON CITY, Nev., May 26, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced full enrollment of the Company's ADDRESS-LC Phase 2 trial evaluating its drug candidate bezisterim for the treatment of neurological symptoms of Long COVID. The Phase 2 study is fully funded by a grant from the U.S. Department of War (DoW, formerly the U.S. Department of Defense). An estimated 15 million U.S. adults reported having long COVID between 2022 and 2023, with 3.8 million experiencing significant lim

CARSON CITY, Nev., May 18, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that the last patient evaluation visit has been completed for the Company's SUNRISE-PD Phase 2 trial evaluating its drug candidate bezisterim in early-stage Parkinson's disease. "With this last patient's treatment visit completed, our team will start the study closeout process, and the Company plans announce topline results in Q3," said Cuong Do, BioVie's President and CEO. "This trial was designed to assess bezisterim's magnitude of therapeutic impact on a s

CARSON CITY, Nev., April 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that it will host a virtual key opinion leader (KOL) event on Thursday, May 7, 2026 at 2:00 PM ET featuring Suzanne de la Monte, MD, MPH (Brown University Warren Alpert Medical School, Providence VA Medical Center), who will join company management to discuss how bezisterim's mechanism of action could potentially address the pathology and progression of neurodegenerative diseases, including Parkinson's disease. To register, click here. The event will provid

CARSON CITY, Nev., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that a poster highlighting the design and enrichment strategy of its ongoing Phase 2 ADDRESS-LC trial will be presented at the Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes, held August 10–13 in Santa Fe, New Mexico.   Long COVID is now recognized as a leading neurological condition that has affected an estimated 400 million individuals worldwide,1,2 .The Centers for Disease Control has reported that 6.9% of adults in the United St

CARSON CITY, Nev., July 24, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, presented "Bezisterim Decreases Biological Age Acceleration in Alzheimer's Disease" at the 2nd World Conference on Aging and Gerentology (WCAG-2025) in Rome, Italy July 14-15, 2025. As the body ages, a natural process called DNA methylation occurs and adds "methyl" groups to the surface of DNA. Accumulated methylation has the impact of interfering with how DNA is decoded and thus has been shown to impact a wide range of dis

CARSON CITY, Nev., July 09, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, presented "Bezisterim Epigenetic Effects on Aging and Neurodegeneration" at the 7th World Aging and Rejuvenation Conference (ARC-2025) taking place in Vienna, Austria, July 9th –10th, 2025. Unlike historical approach to Alzheimer's Disease (AD) treatment that focuses on changing one gene product (e.g., amyloid, p-Tau) at a time, bezisterim modulates inflammation and is believed to help reestablish homeostasis and small changes in

CARSON CITY, Nev., June 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster highlighting the patient-centric design and accessibility of its ongoing SUNRISE-PD Phase 2 clinical trial will be presented at the Advanced Therapeutics in Movement & Related Disorders® Congress, to be held at National Harbor, MD, from June 27-30, 2025. People with Parkinson's disease (PD) often face barriers to accessing specialized care and participating in clinical trials due to delayed diagnos

CARSON CITY, Nev., June 24, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster highlighting the decentralized design and patient experience of its Phase 2 SUNRISE-PD clinical trial evaluating bezisterim (NE3107) in early Parkinson's disease will be presented in poster session at the upcoming Advanced Therapeutics in Movement & Related Disorders® Congress, to be held at National Harbor, MD, from June 27 to June 30, 2025. Details for the poster session are as follows: Title: SUN

Despite growing recognition of long COVID as a serious condition, diagnosed patients have no approved treatment options, with many suffering from debilitating fatigue and brain fog Evidence suggests sustained inflammation plays a central role in the pathogenesis of long COVID, particularly in the associated cognitive dysfunction and other neurological symptoms1 Bezisterim targets key underlying mechanisms of neuroinflammation, and has demonstrated the potential to reduce chronic symptoms in Alzheimer's disease and Parkinson's disease trials thought to be driven by neuroinflammation CARSON CITY, Nev., May 15, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"

CARSON CITY, Nev., May 14, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it will host a virtual key opinion leader (KOL) event featuring Suzanne de la Monte, MD, MPH (Brown University Warren Alpert Medical School, Providence VA Medical Center) and Mark Stacy, MD (Medical University of South Carolina College of Medicine), who will join company management to discuss the unmet need and current treatment landscape for Parkinson's disease on Wednesday, May 28, 2025 at 12:00 PM ET. To re

CARSON CITY, Nev., May 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster on the rationale and design of its Phase 2 SUNRISE-PD clinical trial evaluating bezisterim (NE3107) in early Parkinson's disease will be presented in a Guided Poster Tour session at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025), being held May 7-10, 2025, in New York City. Details for the presentation are as follows: Title: Assessment of Bezisterim (NE3107) in Pati

SUNRISE-PD evaluating the Company's anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson's disease who have not been treated with carbidopa/levodopa SUNRISE-PD is one of very few clinical trials for a Parkinson's disease treatment to incorporate a decentralized approach option to allow for remote participation Patient enrollment has commenced, with recruitment being supported by The Michael J. Fox Foundation, Davis Phinney Foundation and The Parkinson's Foundation Topline data anticipated in Late 2025 or Early 2026 CARSON CITY, Nev., April 16, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company devel

CARSON CITY, Nev., Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that an abstract on the design of its planned Phase 2 trial evaluating bezisterim in Long COVID has been accepted as a poster presentation at the Demystifying Long COVID International Conference, November 21st & 22nd 2024, in Barcelona Spain. The planned Phase 2 study, which is fully funded by a grant from the U.S. Department of Defense (DOD), is a double-blind, randomized (1:1), placebo-controlled, multicenter t

Patents covering BioVie's terlipressin liquid formulation now secured in the United States, India, Japan and Chile, and are pending in eight additional markets Liquid formulation has demonstrated room-temperature stability for up to 24 months, representing an important advantage for treating patients with cirrhosis and ascites in the home-care setting CARSON, Nev., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it has received a Notice of Allowance from the Japan

Patents covering BioVie's terlipressin liquid formulation now secured in the United States, India and Chile, and are pending in nine additional markets Formulation has demonstrated room-temperature stability for up to 24 months, representing an important advantage for treating patients with cirrhosis and ascites in the home-care setting CARSON CITY, Nev., Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it has received a Notice of Allowance from the United States Patent and

Approval from U.S. Army Medical Research and Development Command, Office of Human Research Oversight is the last scientific milestone needed for Company to receivebulk of $13.1 million grant funding Company anticipates Phase 2 trial to commence by early 2025 CARSON CITY, Nev., Sept. 16, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that the U.S. Army Medical Research and Development Command, Office of Human Research Oversight, (OHRO) has approved BioVie's plan to evaluate bezister

Authorization expands use of bezisterim in a Phase 2, placebo-controlled, multicenter trial assessing bezisterim's impact on neurological symptoms associated with long COVID Key milestone reached ahead of schedule, with BioVie on track to receive additional $12.6 million of award from the U.S. Department of Defense and initiate the Phase 2 trial Recent Centers for Disease Control and Prevention survey estimated over 5% of U.S. adults currently have long COVID, and ~3.6 million people reported significantly modifying their activities because of illness1 CARSON CITY, Nev., Sept. 03, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage co

Bezisterim appears to possess broad homeostatic properties relevant to inflammation and human disorders related to aging Patients treated with bezisterim experienced 2 to 4 years age deceleration advantage compared to placebo Bezisterim modulated DNA methylation of proinflammatory genes and appeared to promote the transition of M1 proinflammatory to M2 anti-inflammatory macrophages Bezisterim was associated with 1.5 to 2.3 "fold enrichment" on gene control for hundreds of genes in pathways associated with neurodegenerative disorders and biological processes CARSON CITY, Nev., Aug. 27, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage compa

CARSON CITY, Nev., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster presentation will be shared at the 11th Aging Research and Drug Discovery Meeting (ARDD 2024) being held August 26-30, 2024 in Copenhagen, Denmark. The presentation "Bezisterim Effects on Biological Age, Alzheimer's Epigenetics, and Neurologic Assessments" will provide an overview of clinical data to-date on bezisterim, focusing on various analyses and measurements related to longevity and it

SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson's disease who are naïve to carbidopa/levodopa Company engaged in trial start-up activities and plans to initiate patient screening Q4 2024 CARSON CITY, Nev., Aug. 08, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it has achieved alignment with the Food and Drug Administration (FDA) on its upcoming SUNRISE-PD trial in Parkinson's disease ("PD"). As a result, the

CARSON CITY, Nev., Aug. 06, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company") today announced that the Company's reverse stock split of its issued and outstanding Class A common stock ("Common Stock"), at an exchange ratio of 1-for-10, is now effective. The Company's Common Stock began trading on a split-adjusted basis and will remain listed on The Nasdaq Capital Market under the symbol "BIVI". The new CUSIP number for the Company's Common Stock following the reverse stock split is 09074F405. The effectuation of the reverse stock split followed the approval of the BioVie stockholders at a Special Meeting of Stockholders (the "Special Meeting") on July 29, 2024

SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson's disease who are naïve to carbidopa/levodopa Additional presentation at congress highlighted data from earlier Phase 2a trial of bezisterim in Parkinson's disease that helped inform SUNRISE-PD trial design CARSON CITY, Nev., June 25, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced data from two presentations at the Advanced Therapeutics in Movement and Related Disorder

CARSON CITY, Nev., June 20, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced two poster presentations at the Advanced Therapeutics in Movement and Related Disorders Congress® (ATMRD Congress) being held June 21-25, 2024 in Washington, D.C. The presentation Assessment of Bezisterim (NE3107) in Patients with Early Parkinson's Disease: A Phase 2, Placebo-Controlled Study will outline the study protocol of the Company's upcoming Phase 2 trial evaluating bezisterim people with Parkinson's disea

Full Dataset from Phase 2a trial in Parkinson's Disease suggest patients treated with bezisterim experienced significant improvements in both non-motor symptoms and motor control while placebo-treated patients worsened Improvements in non-motor symptoms correlated with improvements in motor symptoms for Parkinson's Disease patients CARSON CITY, Nev., May 22, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced data from an oral presentation made yesterday at the XXIX World Congress on Parkins

Increasing evidence supports a role for viral persistence, chronic inflammation and immune and metabolic dysregulation in driving long COVID Bezisterim, an anti-inflammatory and insulin-sensitizer that permeates the blood brain barrier, could represent a novel oral treatment targeting an underlying cause of long COVID symptoms CARSON CITY, Nev., April 29, 2024 (GLOBE NEWSWIRE) --  BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the grant of a clinical trial award of up to $13.1 million from the U.S. Department

"Bezisterim" has been approved as the non-proprietary name for NE3107Data shows how bezisterim may be restoring homeostasis via specific genes associated with dementia, metabolism, and inflammation CARSON CITY, Nev., April 25, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including neurological and neuro-degenerative disorders and liver disease, today announced that an oral presentation and poster revealing additional data on how bezisterim potentially restores homeostasis was presented at the 12th Annual Alzheimer's & Parkinson's Drug D

CARSON CITY, Nev., April 18, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that an oral presentation and poster presentation will be shared at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit to be held in Boston, Massachusetts April 23-25. Additionally, the United States Adopted Names (USAN) Council, and the World Health Organization (WHO) International Nonproprietary Names (INN) expert committee has approved "bezisterim" as the non-proprietary (generic) name for NE31

Recently completed financing provides sufficient funds for near-term Parkinson's Disease priority Plans for Phase 2b trial of NE3107 as first-line monotherapy for Parkinson's Disease being finalized with targeted launch late-summer 2024 Once-daily NE3107 formulation expected to be available early 2025 and will be used for Phase 3 trial in Alzheimer's Disease Phase 3 trial for BIV201 in preparation following FDA feedback with guidance on development path; program delayed pending partnership funding CARSON CITY, Nev., March 11, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therap

Data from Phase 2a trial in Parkinson's Disease suggest patients treated with NE3107 experienced significant improvements in non-motor symptoms and motor control while placebo-treated patients worsened Data from Phase 3 trial in mild to moderate Alzheimer's Disease suggest NE3107 may have the potential to realign physiological processes in patients consistent with decreased neurocognitive decline and diseases of aging CARSON CITY, Nev., March 01, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver di

Statistically significant population changes from baseline were observed for all primary and secondary cognitive and functional assessments measured: ADAS-Cog12, ADCS-CGIC, MMSE, CDR, CDR-SB, ADCOMS, and ADL.1  An apparent significant reduction in amyloid burden from baseline was observed in the population. A significant change from baseline was observed in the Amyloid β 42/40 ratio and Amyloid Probability Score as shown by the PrecivityAD® tests from C2N Diagnostics.Increased FDG-PET SUVRs were observed in 10 out of 21 patients in a brain imaging sub-study, which is suggestive of reduced amyloid burden. Statistically significant increases in insulin and beta cell function were observed with

CARSON CITY, Nev., Oct. 19, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that blinded data on cognitive, biomarker, and imaging findings from the recently completed Phase 3 clinical trial (NCT04669028) of NE3107 in the treatment of mild to moderate Alzheimer's Disease will be presented during an oral presentation at the upcoming 16th Clinical Trials on Alzheimer's Disease (CTAD), to be held in Boston, MA from October 24-27, 2023. The presentation Clinical Outcomes From a Phase 3, Rando

CARSON CITY, Nev., Feb. 21, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that BioVie Day will be held March 23, 2023 at 10 a.m. Eastern Standard Time. BioVie Day will provide an opportunity for the Company to provide a synthesis of the data released from its clinical trials over the past 6 months. The Company will share an integrated picture of its progress, an overview of the importance of the reported data when taken in totality and announce plans for advancing the various programs t

Parkinson's disease (PD) patients treated with NE3107 for 28 days experienced a clinically meaningful increase in motor control.Additional data presented at the Clinical Trials in Alzheimer's Disease (CTAD) conference showed that NE3107 enhanced cognition as measured by a variety of assessment tools. Furthermore, a large majority of patients with abnormal MRI scans before treatment showed improvement in one or more brain regions as seen from advanced functional MRI studies after 3 months of treatment with NE3107.NE3107 Appears to Impact Biomarkers of Aging-Related Disease States; Reduces Horvath DNA Methylation SkinBlood Clock by 3.3 years after 3 months of treatment. CARSON CITY, Nev., D

CARSON CITY, Nev., Dec. 06, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced encouraging data suggesting that NE3107 has an impact on improving patients' DNA methylation profiles, potentially impacting biomakers of aging-related disease states. The Phase 2 Investigator-Sponsored Trial (NCT05227820) enrolled a total of 23 patients with an average age of 71.1 years in an open-label, single arm study to measure changes in cognition through verbal and visual test procedures and changes in

NE3107-treated patients experienced greater motor control in Parkinson's trial Patients treated with the combination of NE3107 and levodopa saw improvements in their UPDRS Part 3 (motor) score that is 3+ points superior to patients treated with levodopa alone. This level of superiority is considered to be clinically meaningful by Parkinson's experts. Patients under 70 years of age treated with NE3107/levodopa experienced roughly 6 points superiority compared to those treated with levodopa alone, suggesting that younger patients with less advanced disease progression may experience greater impact from treatment with NE3107.88.9% of patients <70 years old treated with NE3107 and levodopa ex

CARSON CITY, Nev., Nov. 29, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that more than 316 patients have enrolled in its Phase 3 trial, thereby achieving its trial enrollment target. Furthermore, the Company has opted to continue enrolling up to 400 patients without the pre-specified interim data analysis due to NE3107's safety in this study to date and a faster than expected pace of study enrollment. The NM101 trial is a potentially pivotal Phase 3 randomized, double blind, placebo c

CARSON CITY, Nev., Nov. 15, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that three abstracts highlighting results of its Phase 2, open-label study of NE3107 in patients with Alzheimer's Disease (AD) were accepted for presentation at the 2022 Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting, to be held November 29-December 2, 2022 in San Francisco, CA. Details of the presentations are as follows: Oral Presentation:Neuroimaging Data from a Phase 2, open-label St

CARSON CITY, Nev., Oct. 24, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that an abstract characterizing the hospitalization burden of patients with cirrhosis and ascites and receiving treatment via paracentesis has been selected for presentation at The Liver Meeting 2022, the annual meeting of the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting 2022 will be held Washington, DC, from November 4-6, 2022. Details of the poster presentation are as follo

CARSON CITY, Nev., Oct. 19, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that the Company's Phase 2 trial assessing NE3107's potential pro-motoric impact in Parkinson's disease has fully enrolled 44 patients. Topline data readout is expected in December 2022. The NM201 study (NCT05083260) is a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics study in Parkinson's disease (PD) participants treated with carbidopa/levodopa and NE3107. 44 patients with a defined

Positive preliminary data from investigator-sponsored Phase 2 Alzheimer's trial show high proportion of responders and level of cognitive improvements seen for NE3107 confirm NE3107's status as one of the most promising candidates in the Alzheimer's spacePotentially pivotal Phase 3 trial for NE3107 in Alzheimer's has enrolled over half the targeted patients and is on track to readout mid-2023Early and preliminary evidence in Phase 2 Parkinson's trial for NE3107 may suggest findings consistent with that previously seen in non-human primates and should readout before year-end 2022Three significant data readouts expected over the next 12 months CARSON CITY, Nev., Oct. 04, 2022 (GLOBE NEWSWIR

Vast majority of patients saw significant improvements in the Global Rating of Change (overall impression of patient's daily abilities) with NE3107 treatment (p<0.0001 to p<0.05).NE3107 is associated with significant improvements in cognition as evidenced by the ADAS-Cog12 scale. 82% of 17 patients with MMSE >=20 experienced a 2.6 point decrease in ADAS-Cog12 (p=0.0046).Reductions in TNFa (considered to be an initial factor driving inflammation) after NE3107 treatment are significantly correlated with improvement in cognition.NE3107 treatment associated with trending improvements in ratio of p-tau:Ab. 60% of 10 patients with MMSE >=20 improved 0.002 in the ratio of p-tau / Ab (p=0.055).Early

CARSON CITY, Nev., June 23, 2022 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that a patent covering the use of terlipressin monotherapy to treat ascites patients who have not progressed to hepatorenal syndrome ("HRS") has been issued by the U.S. Patent & Trademark Office. This action restores U.S. patent protection for BIV201 (continuous infusion terlipressin), which had previously been lost due to an Inter Partes Review ("IPR") challenge to a related patent by another company. "This newly-iss

CARSON CITY, Nev., March 10, 2022 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that an interview with President and CEO Cuong Do will air on The RedChip Money Report® on Bloomberg TV, March 12, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the United States. The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' experience focused on Discovering Tomorrow's Blue Chips Today™. "The RedChip Money R

RENO, Nev., March 09, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced the participation of its management team in a presentation and one-on-one investor meetings at the Oppenheimer Virtual Annual Healthcare Conference, to be held March 15-17, 2022. Details on the presentation can be found below. Oppenheimer Virtual Annual Healthcare ConferencePresentation Date: Thursday, March 17, 2022Presentation Time: 12:40 PM ETWebcast Link: Click Here About BioVie   BioVie Inc. (NASDAQ:BIVI) is a

RENO, Nev., Jan. 20, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders today announced the treatment of the first patient in the Company's Phase 2 clinical trial assessing the potential pro-motoric impact of its NE3107 asset in Parkinson's disease patients. The NM201 study (NCT05083260) is a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics study in Parkinson's disease (PD). Participants will be treated with carbidopa/levodopa and NE3107 or placebo. Forty patients with a defined

RENO, Nev., Dec. 09, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that the Company is partnering with the American Liver Foundation (ALF) in an educational campaign about chronic liver cirrhosis and its complications and to raise awareness among potential patients and healthcare providers about the Company's Phase 2b Study of BIV201 (continuous infusion terlipressin). The trial— A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients with Cirrhosis and Refracto

RENO, Nev., Dec. 01, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, entered into a debt facility with Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P. (Collectively "the Avenue Venture Funds") providing up to $25 million with the initial $15 million funded at the close on November 30, 2021. "We are pleased to partner with the Avenue Venture Funds as we prepare for a catalyst-rich 2022, which includes anticipated top-line data from both our Phase 2b trial of BIV201 i

SANTA MONICA, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that the FDA has authorized the company to initiate a Phase 2 study assessing NE3107's potential pro-motoric impact in Parkinson's disease patients. The NM201 study (NCT05083260) is a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics study in Parkinson's disease (PD) participants treated with carbidopa/levodopa and NE3107. 40 patients with a defined L-dopa "off state" will be random

SANTA MONICA, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug candidates for the treatment of neurological and neurodegenerative disorders, liver disease and certain cancers, today announced that the Company has enrolled the first patient into the NM101 Phase III clinical study testing NE3107 for the treatment of Alzheimer's Disease (AD). The NM101 study (NCT04669028) is a potentially pivotal Phase 3, randomized, double blind, placebo-controlled, US multicenter study of NE3107 in 316 subjects with mild to moderate AD. In addition to conventional cognition, memory, functional, behavioral and

SANTA MONICA, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease, neurodegenerative disease and certain cancers, announced today that a poster by Christopher L Reading, PhD, BioVie's Executive Vice President for Neuroscience Research & Development was presented at the 2021 Alzheimer's Association International Conference (AAIC). Poster 55458 entitled "Rationale for an anti-inflammatory insulin sensitizer in a phase 3 Alzheimer's Disease trial" highlighted the safety profile and broad mechanism of action against features of Alzheimer's Disease of NE3107—an oral small molecule, blood-brain p